Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline - European Society For Medical Oncology (ESMO)
Cancer-associated thrombosis is a major health problem that affects morbidity and mortality of people with cancer.
Surgical and systemic pharmacological anticancer treatments have a significant impact on the thrombotic risk of patients.
Primary thromboprophylaxis may be considered in high-risk ambulatory cancer patients using validated risk models.
Anticoagulant treatment of VTE in cancer patients is effective but may be associated with increased bleeding.
LMWH or DOACs are effective treatments and generally safe options for cancer-associated thrombosis.
Read full Guideline